Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

Jan 30 2019

• By Emily Hayes

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins accumulated in brain cells that cause their progressive degeneration - Illustration

Related Content

Valbenazine's Consistent But Weak Effect In Tourette Dismays Neurocrine

Dec 13 2018

AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access

Jul 24 2018

Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

Feb 12 2015

Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident

Nov 01 2017

Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival

Aug 22 2017

Related Companies

Neurocrine Biosciences, Inc.

Voyager Therapeutics, Inc

Sanofi

Additional Topics

Deals Commercial Regenerative Medicine Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window